New publication

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M.

Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152. [Epub ahead of print]

Kommentar schreiben

Kommentare: 0